HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting vaccinations for the licensed dengue vaccine: Considerations for serosurvey design.

AbstractBACKGROUND:
The CYD-TDV vaccine was unusual in that the recommended target population for vaccination was originally defined not only by age, but also by transmission setting as defined by seroprevalence. WHO originally recommended countries consider vaccination against dengue with CYD-TDV vaccine in geographic settings only where prior infection with any dengue serotype, as measured by seroprevalence, was >170% in the target age group. Vaccine was not recommended in settings where seroprevalence was <50%. Test-and-vaccinate strategies suggested following new analysis by Sanofi will still require age-stratified seroprevalence surveys to optimise age-group targeting. Here we address considerations for serosurvey design in the context of vaccination program planning.
METHODS:
To explore how the design of seroprevalence surveys affects estimates of transmission intensity, 100 age-specific seroprevalence surveys were simulated using a beta-binomial distribution and a simple catalytic model for different combinations of age-range, survey size, transmission setting, and test sensitivity/specificity. We then used a Metropolis-Hastings Markov Chain Monte-Carlo algorithm to estimate the force of infection from each simulated dataset.
RESULTS:
Sampling from a wide age-range led to more accurate estimates than merely increasing sample size in a narrow age-range. This finding was consistent across all transmission settings. The optimum test sensitivity and specificity given an imperfect test differed by setting with high sensitivity being important in high transmission settings and high specificity important in low transmission settings.
CONCLUSIONS:
When assessing vaccination suitability by seroprevalence surveys, countries should ensure an appropriate age-range is sampled, considering epidemiological evidence about the local burden of disease.
AuthorsNatsuko Imai, Neil M Ferguson
JournalPloS one (PLoS One) Vol. 13 Issue 6 Pg. e0199450 ( 2018) ISSN: 1932-6203 [Electronic] United States
PMID29944696 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Dengue Vaccines
Topics
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Computer Simulation
  • Dengue (epidemiology, immunology, transmission)
  • Dengue Vaccines (immunology)
  • Humans
  • Infant
  • Infant, Newborn
  • Licensure
  • Models, Biological
  • Probability
  • Sensitivity and Specificity
  • Seroepidemiologic Studies
  • Surveys and Questionnaires
  • Vaccination
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: